Loading
A phase 2 trial of nivolumab and pembrolizumab in colorectal cancer, run by Diwakar Davar, now recruiting.
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy is a phase 2, randomised interventional study registered as NCT07223424 by Diwakar Davar, with a registry enrolment figure of 880 participants, started 2025-11-04 and due to reach its primary completion in 2030-11-30. Interventions recorded: nivolumab; pembrolizumab. Conditions listed: Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Colo-rectal Cancer (dMMR/MSI-H CRC); Hepatocellular Carcinoma; Ulcerative Colitis; Esophageal Cancer; Squamous Cell Carcinoma; Gastric/GEJ; Cervical Cancer; Gastro-Esophageal Adenocarcinoma; Esophageal Adenocarcinoma. Primary outcome: Preference for Subcutaneous Nivolumab Treatment; Preference for Subcutaneous Pembrolizumab Treatment. Sites: United States. No results are recorded here; the registry entry is the source.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.